SCHEMBL5133074

SCHEMBL5133074

Cc1c(-c2cccs2)sc2[nH]c(=O)n(CC(C)C)c(=O)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 15/20 0.43
KDM4E B2RXH2 7/20 0.43
HPGD P15428 4/20 0.43
LMNA P02545 3/20 0.43
TDP1 Q9NUW8 4/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
PPARG P37231 3/20 0.39
HTT P42858 3/20 0.39
NCOA2 Q15596 3/20 0.39
NCOA1 Q15788 3/20 0.39
RXFP1 Q9HBX9 3/20 0.39
NPSR1 Q6W5P4 2/20 0.39
ADORA2B P29275 1/20 0.39
MAPT P10636 5/20 0.38
HSD17B10 Q99714 3/20 0.38
GAA P10253 2/20 0.38
CASP1 P29466 2/20 0.38
CASP7 P55210 2/20 0.38
GLA P06280 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5133022 0.87 ALDH1A1 (0.49) ALDH1A1KDM4EHPGDLMNATDP1
SCHEMBL5129549 0.82 GRIN1 (0.47) ALDH1A1KDM4ELMNATDP1MEN1
SCHEMBL5130419 0.81 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDTDP1MEN1
SCHEMBL5132273 0.80 ALDH1A1 (0.44) ALDH1A1KDM4EHPGDLMNATDP1
SCHEMBL5133471 0.76 PDE1A (0.34) ALDH1A1KDM4EHPGDLMNAMEN1
SCHEMBL5132710 0.76 TMIGD3 (0.38) ALDH1A1KDM4EHPGDLMNATDP1
SCHEMBL7203074 0.76 MEN1 (0.43) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL5133070 0.74 PDE1A (0.35) ALDH1A1KDM4ELMNATDP1MEN1
SCHEMBL5132014 0.73 ACACA (0.36)
SCHEMBL5130817 0.72 ADORA2B (0.58) ADORA2BL3MBTL1KDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1989210-A2 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2008-11-12 EP disclosed
WO-2007103776-A2 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2007-09-13 WO disclosed
US-20070208040-A1 e.g. 3-ethyl-5-methyl-1,3-dihydrothiopheno[2,3-d]pyrimidine-2,4-dione; neurodegenerative disorders, antiischemic agent, antidepressant, attention deficit disorder, hepatic fibrosis, cirrhosis of the liver, and drug addiction GILEAD PALO ALTO, INC. 2007-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208040-A1 e.g. 3-ethyl-5-methyl-1,3-dihydrothiopheno[2,3-d]pyrimidine-2,4-dione; neurodegenerative disorders, antiischemic agent, antidepressant, attention deficit disorder, hepatic fibrosis, cirrhosis of the liver, and drug addiction CHRNE, CHRNA3, CHRNA1 ALDH1A1 419/4885KDM4E 635/4885HPGD 1423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.